TNG462

TNG462 is a small-molecule drug developed by Tango Therapeutics and Servier Bio-Innovation. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: A selective PRMT5 inhibitor administered orally, developed for tumours with an MTAP homozygous deletion. ClinicalTrials.gov describes the intervention as: TNG462, a selective PRMT5 inhibitor, will be administered orally. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT05732831, plans to enrol 225 participants with primary completion expected 2027-06. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.